A prospective multicentre study of per-oral endoscopic myotomy (POEM) for achalasia in Australia
- PMID: 33611796
- DOI: 10.5694/mja2.50941
A prospective multicentre study of per-oral endoscopic myotomy (POEM) for achalasia in Australia
Abstract
Objective: To describe the clinical and procedural outcomes of per-oral endoscopic myotomy (POEM) for achalasia in Australia.
Design, setting: Prospective observational study in three Australian tertiary referral centres, 5 May 2014 - 27 October 2019 (66 months).
Participants: Patients who had undergone POEM for achalasia.
Major outcome measures: Eckardt scores calculated prior to POEM and six months, one year, and two years after POEM. The primary outcome was clinical success, defined as an Eckardt score of 3 or less without a second intervention.
Results: 142 patients underwent POEM for achalasia; their mean age was 52 years (SD, 18 years), 83 were men (58%), and the median length of hospital stay two days (IQR, 1-3 days). Their mean Eckardt score before POEM was 8.0 (SD, 2.4) and 1.1 (SD, 1.6) six months after POEM; it did not change significantly between six months and two years after POEM (mean monthly increase, 0.014 points; 95% CI, -0.001 to 0.029). A total of 127 patients (89%) improved clinically after POEM. Intra-procedural capnoperitoneum was the only risk factor associated with treatment failure (adjusted hazard ratio, 2.85; 95% CI, 1.08-7.51). Previous treatments - botulinum toxin injection (25 patients, 18%), endoscopic balloon dilatation (69, 49%), and Heller myotomy (14, 10%) - did not affect POEM outcomes. Five patients (4%) experienced major adverse events, including pneumonia, oesophageal leak, empyema and melaena, that were managed during admission and without sequelae.
Conclusions: POEM is an effective treatment for achalasia. Significant reductions in Eckardt scores achieved by six months are sustained at two years. POEM can be both a first line definitive therapy and a salvage therapy for patients not helped by other treatments.
Keywords: Endoscopy; Esophageal diseases.
© 2021 AMPCo Pty Ltd.
Comment in
-
POEM for achalasia: Looking good, but the final verses are yet to be penned.Med J Aust. 2021 Mar;214(4):171-172. doi: 10.5694/mja2.50945. Med J Aust. 2021. PMID: 33641178 No abstract available.
References
-
- Sadowski D, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil 2010; 22: 256-261.
-
- Samo S, Carlson DA, Gregory DL, et al. Incidence and prevalence of achalasia in Central Chicago, 2004-2014, since the widespread use of high-resolution manometry. Clin Gastroenterol Hepatol 2017; 15: 366-373.
-
- Kahrilas P, Bredenoord A, Fox M, et al; International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27: 160-174.
-
- Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil 2005; 17: 13-21.
-
- Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet 2014; 383: 83-93.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
